Form 4: Gain Therapeutics Director Acquires 15,000 Stock Options

Dov A. Goldstein, a Director and 10% Owner of Gain Therapeutics, Inc., acquired 15,000 stock options with an exercise price of $1.79, vesting over 12 months.

Summary

• Dov A. Goldstein, MD, a Director and 10% Owner of Gain Therapeutics, Inc. (GANX), acquired 15,000 stock options.
• The transaction date for the option grant was June 24, 2025.
• The exercise price for these stock options is $1.79 per share.
• The options vest in 12 equal monthly installments, commencing on July 24, 2025, contingent upon Dr. Goldstein's continuous service.
• The expiration date for these stock options is June 24, 2035.
• Following this reported transaction, Dr. Goldstein directly beneficially owns 15,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive signal, indicating continued alignment of interests between management/insiders and shareholders and confidence in the company's future. As a routine compensation event, it is not overwhelmingly positive but certainly not negative.

Positives

• The acquisition of stock options by a director and 10% owner aligns their financial interests with those of shareholders, as the options gain value only if the company's stock price increases.
• The vesting schedule over 12 equal monthly installments encourages long-term commitment and performance from the director.

Risks

• The value of the stock options is directly tied to the future performance of Gain Therapeutics, Inc.'s common stock; if the stock price does not exceed the exercise price of $1.79, the options may expire worthless.
• The vesting of the options is contingent on the reporting person's continuous service, meaning unvested options could be forfeited if service terminates prematurely.

Future Outlook

This document primarily reports a specific insider transaction (grant of stock options) and its vesting schedule. It does not contain explicit forward-looking statements or guidance regarding the company's future financial performance or strategic direction. The future value of these options is dependent on the company's stock price performance.

Industry Context

The grant of stock options to a director is a common practice across industries, particularly in biotechnology, as a form of equity compensation designed to incentivize long-term commitment and align the interests of key personnel with shareholder value creation. This transaction reflects a standard component of executive and director compensation packages.

Comparison to Industry Standards

• The grant of 15,000 stock options to a director with a 10-year expiration period and a 12-month vesting schedule is a common and standard practice for incentivizing long-term commitment in the biotechnology sector.
• Such grants are typical for directors in small to mid-cap biotech firms like Gain Therapeutics, Inc., aiming to align director interests with shareholder value creation over time.
• The exercise price being at or near the market price on the grant date is also standard for incentive options, ensuring that the options only become valuable if the company's stock price appreciates.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price, potentially encouraging decisions that benefit long-term stock performance.

Next Steps

• The acquired stock options will begin vesting in 12 equal monthly installments starting July 24, 2025.
• The reporting person will continue to hold these options, subject to vesting, until their expiration on June 24, 2035, or earlier exercise/forfeiture.

Key Dates

Keywords

Gain Therapeutics, GANX, Form 4, SEC filing, insider transaction, stock options, beneficial ownership, director compensation, equity compensation